PharmacoEconomics & Outcomes News 680 - 15 Jun 2013 Infliximab best choice in plaque psoriasis Infliximab, given IV at a dose of 3 mg/kg, is the most cost-effective biologic agent for the treatment of patients with plaque psoriasis. This is the main finding of a US study * that compared the cost effectiveness from a third-party payer perspective of five biologic agents currently available for the treatment of moderate-to-severe plaque psoriasis: SC adalimumab 40mg or 80mg every other week, or 40mg every other week with an initial loading dose (2 × 40mg or 1 × 80mg); IM alefacept 0.025, 0.075 or 0.150 mg/kg as well as 10 or 15mg, once weekly; SC etanercept 25 or 50mg, once or twice weekly; IV infliximab 3 or 5 mg/kg for 3 infusions; and SC ustekinumab 45 or 90mg, given twice. Infliximab 3 mg/kg was the most cost-effective biologic agent with regard to the cost per patient achieving PASI-75 ** ($US9742; 2010 values) and per patient achieving a DLQI MID *** ($3938). The next most cost-effective agent for PASI-75 outcomes was adalimumab 40mg every other week, with or without an 80mg loading dose ($11 869 and $13 299, respectively), followed by infliximab 5 mg/kg ($13 548). * The study was supported by Galderma Laboratories, L.P. ** a 75% improvement in the Psoriasis Area Severity Index *** minimally important difference in the Dermatology Life Quality Index Ahn CS, et al. Cost Effectiveness of Biologic Therapies for Plaque Psoriasis. American Journal of Clinical Dermatology : 22 May 2013. Available from: URL: http://dx.doi.org/10.1007/s40257-013-0030-z 803088227 1 PharmacoEconomics & Outcomes News 15 Jun 2013 No. 680 1173-5503/10/0680-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Infliximab best choice in plaque psoriasis

Download PDF Report

Upload
lillian-turner
View
212
Download
0

Embed Size (px)

Citation preview

PharmacoEconomics & Outcomes News 680 - 15 Jun 2013

Infliximab best choice in plaquepsoriasis

Infliximab, given IV at a dose of 3 mg/kg, is the mostcost-effective biologic agent for the treatment of patientswith plaque psoriasis.

This is the main finding of a US study* that comparedthe cost effectiveness from a third-party payerperspective of five biologic agents currently available forthe treatment of moderate-to-severe plaque psoriasis:SC adalimumab 40mg or 80mg every other week, or40mg every other week with an initial loading dose(2 × 40mg or 1 × 80mg); IM alefacept 0.025, 0.075 or0.150 mg/kg as well as 10 or 15mg, once weekly; SCetanercept 25 or 50mg, once or twice weekly; IVinfliximab 3 or 5 mg/kg for 3 infusions; and SCustekinumab 45 or 90mg, given twice.

Infliximab 3 mg/kg was the most cost-effectivebiologic agent with regard to the cost per patientachieving PASI-75** ($US9742; 2010 values) and perpatient achieving a DLQI MID*** ($3938). The next mostcost-effective agent for PASI-75 outcomes wasadalimumab 40mg every other week, with or without an80mg loading dose ($11 869 and $13 299, respectively),followed by infliximab 5 mg/kg ($13 548).* The study was supported by Galderma Laboratories, L.P.** a 75% improvement in the Psoriasis Area Severity Index*** minimally important difference in the Dermatology Life QualityIndex

Ahn CS, et al. Cost Effectiveness of Biologic Therapies for Plaque Psoriasis.American Journal of Clinical Dermatology : 22 May 2013. Available from: URL:http://dx.doi.org/10.1007/s40257-013-0030-z 803088227